Aimmune Therapeutics Stock News

The U.S. Food and Drug Administration on Wednesday recommended switching to virt...

An analyst called the patch "dead in the water," also noting that the ongoing Covid-19 pandemic could challenge the rollout of a competing therapy, Aimmune's Palforzia, which the FDA approved in Janua

U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clinical trial due to the coronavirus outbreak, as drug developers begin taking preventive measures to contain the fast-s…

U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clin...

U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clinical trial due to the coronavirus outbreak, as the drug developer said it would postpone recruitment for a trial of i…

U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clin...

Osmotica Pharmaceuticals (NASDAQ:OSMT) initiated with Buy rating and $8 (74% upside) price target at SunTrust.Epizyme (NASDAQ:EPZM) added to Best Ideas List at Wedbush with a $30 (68% upside) price ta

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron P

From social distancing for patients to company representatives meeting with allergists and payers, the rollout of the drug is anything but normal.

The COVID-19-induced sell-off has taken a toll on stocks across sectors. An analyst at Cantor Fitzgerald presented his take on how biotech investing could look after the coronavirus pandemic and highl

In its latest earnings call, ACRX said it will acquire Tetraphase. AIMT reports more positive data in peanut allergy follow on study. Stemline reports results.

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced eff

DBV Technologies (NASDAQ:DBVT) craters 45% premarket on increased volume in reaction to its announcement that the FDA, during its review of its marketing application for Viaskin Peanut, has identifi

(BFM Bourse) - Le parcours d'obstacle de la biotech tricolore pour essayer de faire homologuer son traitement de l'allergie à l'arachide par la FDA se …

Aimmune Therapeutics Inc on Monday warned of a slow launch of its peanut allergy...